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Abstract: Background: Understanding the pathophysiologic mechanism of intracranial aneurysm
(IA) formation is a prerequisite to assess the potential risk of rupture. Nowadays, there
are neither reliable biomarkers nor diagnostic tools to predict the formation or the
evolution of IA. Increasing evidence suggests a genetic component of IA but genetics
studies have failed to identify genetic variation causally related to IA.
Objective:  To develop diagnostic and predictive tools for the risk of IA formation and
rupture.
Methods: The French ICAN project is a non-interventional nationwide and multi-centric
research program. Each typical IA of bifurcation will be included. For familial forms,
further IA screening will be applied among first-degree relatives. By accurate
phenotype description with high-throughput genetic screening, we aim to identify new
genes involved in IA. These potential genetic markers will be tested in large groups of
patients.  Any relevant pathway identified will be further explored in a large cohort of
sporadic carriers of IA, which will be well documented with clinical, biological and
imaging data.
Expected outcomes: Discovering genetic risk factors, better understanding the
pathophysiology and identifying molecular mechanisms responsible for IA formation
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will be essential bases for the development of biomarkers and identification of
therapeutic targets.
Discussion:
Our protocol has many assets. A nationwide recruitment allow for the inclusion of large
pedigrees with familial forms of IA. It will combine accurate phenotyping and
comprehensive imaging with high-throughput genetic screening. Last, it will enable
exploiting meta-data to explore new pathophysiological pathways of interest by
crossing clinical, genetic, biological and imaging information.
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Additional Information:
Question Response
Significance of the Work:
Please include a brief statement
summarizing the significance of the work
and in particular how it differs from and
advances existing literature.
We launch an ambitious multicenter project (I CAN) addressing the pathophysiology of
IA. To date, no transmitted variation related to familial forms of IA has been published.
Our protocol has many assets. First, our nationwide recruitment allow for the inclusion
of large pedigrees with familial forms of IA. Second, it will combine accurate
phenotyping and comprehensive imaging with high-throughput genetic screening. Last,
it will enable exploiting meta-data to explore new pathophysiological pathways of
interest by crossing clinical, genetic, biological and imaging information. This should
lead us to identify the biological pathways involved in the formation of IA. Currently no
blood test has been established to help in diagnosing IA, and there is still no way to
predict the natural history of an IA. Discovering relevant biomarkers would undoubtedly
facilitate early detection, risk assessment and therapeutic monitoring of IA.
Compliance with Research Reporting
Guidelines:
Neurosurgery endorses several reporting
guidelines and requires authors to submit
their research articles in accordance with
the appropriate guideline statement(s)
and checklist(s). Completed applicable
checklists and flow diagrams must be
included with submissions.
Research articles that must be submitted
according to the appropriate reporting
Yes - Submission Adheres to Appropriate Reporting Guideline(s) and Applicable
Checklists/Materials Are Included
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guideline(s) include, but are not limited to:
randomized trials, systematic reviews,
meta-analyses of interventions, meta-
analyses of observational studies,
diagnostic accuracy studies, and
observational epidemiological studies (eg,
case series, cohort, case-control, and
cross-sectional studies). Consult the
EQUATOR Network, which maintains a
useful, up-to-date list of guidelines as they
are published, with links to articles and
checklists: http://www.equator-
network.org.
Please confirm below that information is
reported according to the relevant
reporting guideline(s) and any required
materials are included with the
submission:
Please indicate which reporting
guideline(s) the study adheres to (eg,
STROBE, PRISMA, CONSORT).
 as follow-up to "Compliance with
Research Reporting Guidelines:
Neurosurgery endorses several reporting
guidelines and requires authors to submit
their research articles in accordance with
the appropriate guideline statement(s)
and checklist(s). Completed applicable
checklists and flow diagrams must be
included with submissions.
Research articles that must be submitted
according to the appropriate reporting
guideline(s) include, but are not limited to:
randomized trials, systematic reviews,
meta-analyses of interventions, meta-
analyses of observational studies,
diagnostic accuracy studies, and
observational epidemiological studies (eg,
case series, cohort, case-control, and
cross-sectional studies). Consult the
EQUATOR Network, which maintains a
useful, up-to-date list of guidelines as they
are published, with links to articles and
checklists: http://www.equator-
network.org.
Please confirm below that information is
reported according to the relevant
reporting guideline(s) and any required
materials are included with the
submission:"
STROBE
Statistical Analysis:
For manuscripts that report statistics, the
Editor requires that the authors provide
evidence of statistical consultation or
expertise.
If your article includes statistics, has the
Not Applicable - Article does not report statistics.
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information reported been evaluated by
an expert?
IRB/Ethics Approval:
Please indicate if your study has received
institutional review board/ethics approval.
If yes, these materials are readily
available should the Editor request them.
Yes
Funding:
Study Protocols must have received grant
funding from a major extramural funding
body at the time of submission. Please
provide the name of the sponsor/funding
agency below.
This study was supported by a grant from the French Ministry of Health (ANR-DGOS
2015), the INSERM (UMR 1087) and the GENAVIE fundation
Trial Registration:
Please provide the trial registration
information for the study below. Include
the trial registry, along with the unique
identifying number.
The ICAN project is a non-interventional clinical research, approved by the Institutional
Review Boards and Ethics Committees of Nantes.Informed written consent has been
obtained from all patients.The ICAN study group is constituted in France of one
coordinating center (University Hospital of Nantes), one genotyping center (Inserm
UMR 1087) and 23 clinical centers of recruitment.
This study has been registered in Clinical Trial under the reference RC15_0304.
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Dear Mr Nelson M.Oyesiku,  
In hopes of being published in your journal, we are pleased to offer you a proposal of our 
work, entitled "Understanding the pathophysiology of intracranial aneurysm: The ICAN 
project" 
To this day, despite enormous progress in sequencing, the field of genetics has not been able 
to elucidate any signaling pathway involved in intracranial aneurysm formation.  
We have developed a nationwide collaborative project gathering neuroradiologists, 
neurosurgeons, neurologists ,geneticists, cardiologists, ophthalmologists, vascular specialists 
and biologists with the aim of discovering genes and pathways involved in this major health 
problem.  
Our project addresses the urgent and obvious need to develop diagnostic and predictive 
tools of risk of IA formation and rupture. Discovering genetic risk factors, better 
understanding the pathophysiology and identifying molecular mechanisms responsible for IA 
formation will be essential bases for the development of biomarkers and identification 
oftherapeutic targets 
Our study raises important questions and encourages novel reflection on the issue of 
physiopathology of intracranial aneurysms.  
Others works stemming from this project are to be published, particularly with the first 
results of genetic analysis of the most informative families.  
All authors have seen and approved the content and have contributed significantly to the 
work. No author has any related conflict of interest to disclose regarding this work. 
Our study should be frequently cited and could represent a significant contribution to the 
journal. Finally, this manuscript has not been submitted elsewhere. 
We hope you find our manuscript suitable for publication. 
Sincerely, 
RomainBourcier 
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ABSTRACT 
Background: Understanding the pathophysiologic mechanism of intracranial aneurysm (IA) 
formation is a prerequisite to assess the potential risk of rupture. Nowadays, there are neither 
reliable biomarkers nor diagnostic tools to predict the formation or the evolution of IA. 
Increasing evidence suggests a genetic component of IA but genetics studies have failed to 
identify genetic variation causally related to IA.  
Objective:  To develop diagnostic and predictive tools for the risk of IA formation and rupture.  
Methods: The French ICAN project is a non-interventional nationwide and multi-centric 
research program. Each typical IA of bifurcation will be included. For familial forms, further IA 
screening will be applied among first-degree relatives. By accurate phenotype description with 
high-throughput genetic screening, we aim to identify new genes involved in IA. These potential 
genetic markers will be tested in large groups of patients.  Any relevant pathway identified will 
be further explored in a large cohort of sporadic carriers of IA, which will be well documented 
with clinical, biological, and imaging data. 
Expected Outcomes: Discovering genetic risk factors, better understanding the pathophysiology 
and identifying molecular mechanisms responsible for IA formation will be essential bases for 
the development of biomarkers and identification of therapeutic targets. 
Discussion: Our protocol has many assets. A nationwide recruitment allows for the inclusion of 
large pedigrees with familial forms of IA. It will combine accurate phenotyping and 
comprehensive imaging with high-throughput genetic screening. Last, it will enable exploiting 
meta-data to explore new pathophysiological pathways of interest by crossing clinical, genetic, 
biological, and imaging information.  
Keywords: Aneurysm, Familial, Genetics, Pathophysiology 
Short Title: The ICAN Project 
Manuscript
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GENERAL INFORMATION 
Title: Understanding the pathophysiology of intracranial aneurysm: The ICAN project 
Study Dates: May 2016 to May 2019; this study is ongoing. 
Funding Agencies: This study was supported by a grant from the National Research Agency and 
the French Ministry of Health (ANR-DGOS 2015), Agence Nationale de la Recherche, 50, 
avenue Daumesnil,  75012 PARIS, 01.78.09.80.00   – DGOS 14 Avenue Duquesne, 75007 Paris, 
France,  01 40 56 60 00, The French Regional Council of Pays de la Loire (RFI VaCaRMe), 
Hôtel de la région 1, rue de la Loire 44966 Nantes Cedex 9, 02 28 20 50 00, and The Fondation 
GENAVIE 8 Quai Moncousu, 44000 Nantes, France, 02 28 08 01 13. 
Registry: (Clinical Trial) RC15_0304 
Investigators: The project Management is ensured by Dr. Romain Bourcier MD and Pr. Hubert 
Desal MD Ph D from the Department of Neuroradiology of the Centre Hospitalier Universitaire 
of Nantes, 8 Quai Moncousu, 44000 Nantes, France. 
L’institut du thorax, INSERM Unit 1087, CNRS, Centre Hospitalier Universitaire of Nantes, 8 
Quai Moncousu, 44000 Nantes, France, 02 28 08 01 13, particularly the director Richard Redon 
PhD, ensures the genetic analysis. The co-director of the unit, Gervaise Loirand PhD is 
responsible of the functional analysis for candidate genes. 
The ICAN study group is constituted in France of 1 coordinating centre (Centre Hospitalier 
Universitaire of Nantes), 1 genotyping centre (L’institut du thorax, INSERM Unit 1087, CNRS, 
Centre Hospitalier Universitaire of Nantes) and 22 clinical centers of recruitment. 
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RATIONALE AND BACKGROUND INFORMATION 
Intracranial aneurysms (IA) are acquired cerebrovascular abnormalities affecting 3% of the 
general population (mean age 50 years).1 They are characterized by a localized dilation and wall 
thinning in typical locations in intracranial arteries2. The most notorious and deleterious 
complication of an IA is the rupture, resulting in subarachnoid hemorrhage that can lead to 
severe disability and death3 . Unfortunately, there are neither reliable biomarkers nor diagnostic 
tools to predict the formation and/or the evolution of an IA in any given individual. Current 
treatments are more or less invasive (microsurgical or endovascular treatment) with a risk of 
procedural morbidity/mortality4. 
Although the pathogenesis of IA has been the subject of several studies for many years, the 
mechanisms underlying their formation, growth and eventual rupture are largely unknown5. IA 
are mostly acquired lesions resulting form a defective vascular wall response to local 
hemodynamic stress6. The structural deterioration of the arterial wall involves inflammation and 
tissue degeneration with degradation of the extracellular matrix and smooth muscle cell 
apoptosis7. Risk factors such as hypertension, female sex, increasing age, cigarette smoking, 
excessive alcohol consumption, and familial history of aneurysm, predispose to IA formation and 
rupture8. Furthermore, increasing evidence suggest a genetic component of IA formation 9. 
Genome wide association studies and subsequent replication case-control studies identified 
variants on chromosomes 4q31-23, 8q11 and 9p21.3 that were strongly associated with IA 
formation10. However, these loci explain only 5% of the familial inheritance cases 11 .  
 
STUDY GOALS AND OBJECTIVES 
Our project addresses the urgent and obvious need to develop diagnostic and predictive tools of 
risk of IA formation and rupture. Discovering genetic risk factors, better understanding the 
pathophysiology and identifying molecular mechanisms responsible for IA formation will be 
essential bases for the development of biomarkers and identification of therapeutic targets. 
 
STUDY DESIGN 
For this global project including observational and basic science research, we have developed a 
 4 
nationwide collaborative project gathering neuroradiologists, neurologists, neurosurgeons, 
geneticists, cardiologists, ophthalmologists, vascular specialists, and biologists. 
 
IA Phenotype Definition 
A typical IA is defined as a saccular arterial dilatation occurring at a bifurcation of the 
intracranial vasculature. Neuroradiological phenotyping is performed in each center by 
experienced interventional neuroradiologists, neurologists, and neurosurgeons, in order to 
exclude other IA types and to recruit only the typical saccular bifurcation IA. 
IA are recorded as follows for all the cases included in the study: 
 
“Certain” 
if an imaging exam demonstrates a typical IA of bifurcation whatever the measurement, 
or 
if medical records document the presence of a typical IA of bifurcation on cerebral angiogram, 
operative report or autopsy. 
 
“Uncertain” 
if an imaging exam demonstrates an ectasia measuring < 2 mm, 
or 
if medical records document the presence of a subarachnoid hemorrhage without traumatism 
on cerebral angiogram, operative report or autopsy. 
 
Inclusion and Exclusion Criteria 
Inclusion Criteria 
 Familial cases of IA: Subject carrying a certain IA and at least 1 first-degree relative with 
a certain IA (no age limit). 
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 Healthy first-degree relatives: Subject of 20 years or more and having at least 2 first-
degree relatives with a certain IA. For these, an MRI screening will be proposed. 
 Sporadic cases of IA: Subject aged 20 years or more with a certain IA. 
 
Exclusion Criteria 
 A mycotic, fusiform-shaped, or dissecting IA, an IA in relation with an arteriovenous 
malformation. 
 A family history of polycystic kidney disease, Ehlers Danlos Syndrome, Marfan's 
syndrom, fibromuscular dysplasia, or Moya-Moya disease. 
 A failure to obtain informed consent. 
 
METHODOLOGY 
 
Recruitment Process 
 
Recruitment of Familial Cases and Relatives 
Once a potential family is identified, the proband is asked to complete a family history 
questionnaire; study information sheets and recruitment letters are provided for later distribution 
to additional family members. Each relative expressing his/her interest to the proband is then 
contacted by phone. 
If he/she meets the inclusion criteria, MRI screening and blood sampling are proposed. In order 
to optimize the recruitment of large families, only clinical centers with extensive experience in 
clinical management and IA imaging were selected as recruitment sites.  
For each family selected for primary genetic investigations (ie, exome sequencing), the IA 
phenotype will be further assessed. First, a medical genetics consultant will check whether IA 
occurrence may result from any syndromic disease (such as Marfan disease or vascular forms of 
Elhers Danlos).Then eye fundus, transthoracic echocardiography, non-invasive analysis of 
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endothelial dysfunction, and echography Doppler analysis of peripheral arteries (sub clavians, 
radials, femorals, renals, digestives, etc) will be carried out  in order to test any other vascular 
malformation or variation potentially linked to the presence of IA, thus constituting a syndrome 
yet unknown. 
 
Recruitment of Sporadic Cases 
A patient with a certain and typical IA of bifurcation seen in consultation will be included, 
regardless of a history of rupture or treatment.  
 
Data recorded 
 
Clinical Data 
Data related to environmental risk factors are collected for each included patient. Smoking 
history is recorded as: 
 never smoked 
 stopped smoking for more than 3 years 
 stopped smoking for less than 3 years or current smoker 
If the patient was a current or former cigarette smoker, the number of pack-years prior to 
diagnosis of IA is evaluated.  
Parameters as high blood pressure defined as a past history of hypertension prior to the diagnosis 
of IA, diabetes mellitus, hypercholesterolemia, alcohol consumption, body mass index, history of 
migraine (according to the International Headache Society) or of cryptogenic cephalalgia, 
medical treatment by statins, antiplatelet agents, vitamin K antagonists, long term intake of anti-
inflammatory drugs and hormone replacement therapy are recorded. 
History of ruptured IA, stroke, carotid stenosis, ischemic heart disease, lower limbs occlusive 
arterial disease, cancer, hematologic disorder is also recorded. 
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Biological Data 
The bio collection will consist of blood sampling taken from each included patient; 2 tubes for 
DNA analysis and 2 tubes for serum extraction.  
 
Imaging Data 
IA imaging in first-degree relatives is assured by MRI/MRA with the following protocol: MR 
angiography Time of Flight, FLAIR, Gradient Echo T2-weigthed imaging. The sensitivity of 
MRI in detecting IA ranges from 81 to 95 % 12–20. The inter-observer consistency, particularly 
for IA > 3 mm is good to excellent (kappa 0.59–0.82) 13,15–17,19,21. 
Angiographic imaging will allow recording all parameters regarding the aneurysm form (height, 
width, neck size, the presence of lobulation, or wall irregularities) and the parent artery diameter.  
Any cervical loop of the carotid artery, hypoplasic first segment of the anterior cerebral artery, 
basilar or vertebral fenestration, and foetal type of posterior cerebral artery will also be registered. 
On the FLAIR imaging sequences, the presence of vascular white matter disease (graded 
according to the Fazekas classification22),  territorial ischemic sequelae, inflammatory white 
matter disease, atypical white matter disease evocative of Col4a1 mutation or Fabry disease will 
be noted. 
On Gradient Echo T2-weigthed imaging, we will quantify the presence of microbleeds in the 
deep or superficial brain parenchyma. 
Some patients, particularly the sporadic cases of IA, that had independently undergone MRI, 
computed tomography angiography or digital subtraction angiography for their standard clinical 
care will be reviewed in a blinded manner by neuroradiologists from the coordinating center. 
Imaging files will be uploaded on a global server for each included patient (SHANOIR). 
 
DISCUSSION 
 
National Recruitments in France 
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Because populations living in rural areas of western France have been sedentary for centuries, 
this geographical area is a preferred location to detect and recruit large families with hereditary 
diseases. By a systematic research of familial history of IA, we have already recruited more than 
100 families. We have then selected 4 large families with 4 or more relatives harboring IA for 
primary genetic investigations based on whole exome sequencing (Figure 1). In relation with our 
network, we will also ensure the recruitment of sporadic IA (without familial screening) to 
constitute a collection of clinical, biological, genetic, but also imaging data of patients with IA. 
Whole Exome Sequencing 
Whole exome sequencing allows systematic detection of genetic variation across the whole 
coding portion of the human genome. By this method, one can list the rare genetic variants that 
are shared between several related individuals affected by IA. The coding portion of the genome 
is captured then sequenced. After read alignment and variant calling, a series of filters are 
applied. 
Further Testing of Candidate Genes 
In a second step, any candidate genes selected through whole exome sequencing on familial 
cases are further tested on an extended group of unrelated familial IA carrier, which is currently 
under construction through our clinical network. In order to test the presence of rare variants 
associated to IA in this cohort, rare-variants association studies will be performed 
In addition, the most promising candidates are subjected to preliminary functional investigations, 
to check whether their biological activity is relevant to the pathophysiology of IA. 
Exploiting Diverse and Massive Datasets 
Discovering or validating novel risk factors in IA relies in the setup of a data infrastructure 
capable of jointly exploiting diverse and possibly massive datasets (whole exome sequencing, 
multi-modality imaging, and clinical data). Based on such a linked data infrastructure, we can 
imagine in silico validation scenarios, ie, algorithms, querying and combining diverse clinical 
features (age, hypertension, and smoking habits) with circulating or quantitative imaging 
biomarkers. Following the FAIR (Findable, Accessible, Interoperable, and Reusable) data 
principle and technically adopting a Linked Data approach (structured metadata, reference 
controlled vocabularies or ontologies) will allow: (i) to query, filter, and join these 
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heterogeneous datasets from multiple viewpoints, and (ii) to open data reuse perspectives, 
beyond the project timeframe and beyond its initial objectives.  
Conclusion 
We launch an ambitious multicenter project (ICAN) addressing the pathophysiology of IA. To 
date, no transmitted variation related to familial forms of IA has been published. Our protocol 
has many assets. First, our nationwide recruitment allows for the inclusion of large pedigrees 
with familial forms of IA. Second, it will combine accurate phenotyping and comprehensive 
imaging with high-throughput genetic screening. Last, it will enable exploiting meta-data to 
explore new pathophysiological pathways of interest by crossing clinical, genetic, biological, and 
imaging information. This should lead us to identify the biological pathways involved in the 
formation of IA. Currently no blood test has been established to help in diagnosing IA, and there 
is still no way to predict the natural history of an IA. Discovering relevant biomarkers would 
undoubtedly facilitate early detection, risk assessment, and therapeutic monitoring of IA.  
 
TRIAL STATUS 
This is an ongoing study 
 
SAFETY CONSIDERATIONS 
No adverse event is expected in this non-interventional study. 
 
FOLLOW-UP 
We are building a biocollection but in the close follow-up and depending on the grants obtained, 
this project will probably become a cohort study with a follow-up corresponding to the 
recommendation for IA management. 
 
EXPECTED OUTCOMES OF THE STUDY 
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Discovering biomarkers correlated with the presence of IA should allow better detection and 
prevention of IA rupture. In the longer term, our systematic nationwide collection of each typical 
IA of bifurcation together with the registration of clinical, biological, genetic, and morphological 
data will allow deciphering the pathophysiology of this orphan, frequent, and serious 
cerebrovascular disease. 
 
DURATION OF THE PROJECT 
We have initially scheduled a recruitment period of 3 years (May 2016 to May 2019) but 
according to the evolution of the project we can move towards a cohort study making the project 
more sustainable. 
 
PROJECT MANAGEMENT 
The project Management is ensured by Dr. Romain Bourcier MD and Pr. Hubert Desal MD Ph D 
from the Department of Neuroradiology of the Centre Hospitalier Universitaire of Nantes, 8 Quai 
Moncousu, 44000 Nantes, France. 
L’institut du thorax, INSERM Unit 1087, CNRS, Centre Hospitalier Universitaire of Nantes, 8 
Quai Moncousu, 44000 Nantes, France, 02 28 08 01 13, particularly the director Richard Redon 
PhD, ensures the genetic analysis. The co-director of the unit, Gervaise Loirand PhD is 
responsible of the functional analysis for candidate genes. 
The ICAN study group is constituted in France of 1 coordinating centre (Centre Hospitalier 
Universitaire of Nantes), 1 genotyping centre (L’institut du thorax, INSERM Unit 1087, CNRS, 
Centre Hospitalier Universitaire of Nantes) and 22 clinical centers of recruitment. 
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FIGURE LEGEND 
 
Figure 1: Pedigree of a 3 generation family with 6 patients affected by IA. Arrows indicate 
probands. Asterisks indicate exome-sequenced individuals.  
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